Efficacy of Viabahn in the treatment of severe superficial femoral artery lesions: which factors influence long-term patency?
OBJECTIVE
To evaluate superficial femoral artery (SFA) occlusive disease treatment by means of covered stents.


METHODS
retrospective.


METHODS
From 2000 to 2005, a Hemobahn/Viabahn endoprosthesis was implanted in 102 limbs (95 patients; mean age: 72.1 years, 52-94) for intermittent claudication (group I, n=50 limbs), critical (group II, n=32) or acute ischemia (group III, n=20). Lesions treated were Trans-Atlantic Inter-Society Consensus (TASC) A (n=9) B (n=42), C (n=28) or D (n=23), associated with a good (2 or 3 leg arteries, n=60) or a poor (1 or 0 artery, n=42) runoff.


RESULTS
The endograft was placed successfully in all cases, but 3 early deaths (3.2%) (1 in group II and 2 in group III), and 4 acute thromboses (4%) occurred. Primary and secondary actuarial patency rates were 97+/-1.7%, and 99+/-1% at 1 month, 74+/-4.8% & 84+/-4.1% at 1 year,and 71+/-9.5% & 79+/-8.5% at 3 years, after a mean follow-up of 30.2 months (1-60). Long-term primary and secondary patencies were significantly different between TASC Cand TASC D lesions (P<.004 & .001).


CONCLUSIONS
Severity of lesions, rather than preoperative symptoms or runoff, is mainly to be considered before using Hemobahn/Viabahn endoprosthesis in severe SFA occlusive lesions.
Alimi
Y S
YS
Department of Vascular Surgery, University Hospital Nord, Marseille, France. yves.alimi@ap-hm.fr
Hakam
Z
Z
Hartung
O
O
Boufi
M
M
Barthèlemy
P
P
Aissi
K
K
Dubuc
M
M
D000368:Aged; D000369:Aged, 80 and over; D001157:Arterial Occlusive Diseases / Q000453:epidemiology / Q000601:surgery*; D001807:Blood Vessel Prosthesis; D005260:Female; D005263:Femoral Artery; D006801:Humans; D007383:Intermittent Claudication / Q000601:surgery; D007511:Ischemia / Q000601:surgery*; D053208:Kaplan-Meier Estimate; D007866:Leg / Q000098:blood supply; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D011474:Prosthesis Design; D012307:Risk Factors; D015607:Stents; D016896:Treatment Outcome; D014654:Vascular Patency